The lawsuit alleges that GRAIL, Inc. misled shareholders by masking the true status of its NHS-Galleri study. While the company maintained a positive outlook, the complaint asserts that executives concealed data suggesting the trial’s three-year follow-up period was insufficient to meet its primary endpoint: a reduction in Stage III-IV cancers. By withholding critical trendlines and refusing to disclose topline results, the company allegedly left investors unprepared for the February 19, 2026, announcement that the trial had failed to demonstrate statistical significance.

Following the disclosure, the company’s stock price plummeted from $101.53 to $50.21 in a single session. The Gross Law Firm is now organizing the class action to recover losses incurred from these allegedly deceptive practices. Participation in the litigation requires no upfront cost or obligation, and shareholders are encouraged to register their claims before the August 4 cutoff to participate in the recovery process.